Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Non-Current Debt (2016 - 2017)

Lisata Therapeutics filings provide 8 years of Non-Current Debt readings, the most recent being $23290.0 for Q2 2017.

  • For the quarter ending Q2 2017, Non-Current Debt fell 99.39% year-over-year to $23290.0, compared with a TTM value of $23290.0 through Jun 2017, down 99.39%, and an annual FY2016 reading of $2.5 million, up 333.06% over the prior year.
  • Non-Current Debt hit $23290.0 in Q2 2017 for Lisata Therapeutics, down from $215985.0 in the prior quarter.
  • The five-year high for Non-Current Debt was $13.9 million in Q4 2014, with the low at $23290.0 in Q2 2017.
  • Median Non-Current Debt over the past 5 years was $1.3 million (2015), compared with a mean of $3.1 million.
  • The sharpest move saw Non-Current Debt skyrocketed 2515.08% in 2014, then plummeted 99.39% in 2017.
  • Year by year, Non-Current Debt stood at $531164.0 in 2013, then soared by 2515.08% to $13.9 million in 2014, then tumbled by 95.8% to $583041.0 in 2015, then surged by 333.06% to $2.5 million in 2016, then crashed by 99.08% to $23290.0 in 2017.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $23290.0, $215985.0, and $2.5 million for Q2 2017, Q1 2017, and Q4 2016 respectively.